Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Novo Nordisk to present 39 abstracts at the 78th Annual American Diabetes Association Scientific Sessions | ||
By: PR Newswire Association LLC. - 18 Jun 2018 | Back to overview list |
|
PLAINSBORO, N.J., June 18, 2018 /PRNewswire/ -- Novo Nordisk today announced that the company will share data from 39 abstracts discussing a breadth of new clinical, real-world and patient perspectives data across its portfolio of pipeline and marketed products at the upcoming 78th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla., U.S. from June 22-26, 2018. "Our expanding portfolio, investigational pipeline and 95-year commitment to people with diabetes allows us to contribute to the growing body of scientific evidence to better understand this condition and its many related comorbidities," said Todd Hobbs, vice president and US chief medical officer of Novo Nordisk. "We're pleased to provide additional insights at this year's congress with a range of data, including real-world evidence and perspectives from healthcare professionals and patients, to help guide better treatment decisions." Following are key highlights that will be presented at the meeting: June 23, 11:30 AM – 12:30 PM ET, poster presentation
June 23, 12:30 – 1:30 PM ET, moderated poster presentation
June 23, 5:15 PM ET, oral presentation
June 23, 5:45 PM ET, oral presentation
June 24, 12:00 – 1:00 PM ET, moderated poster presentation
June 24, 12:00 – 1:00 PM ET, poster presentation
June 25, 12:00 – 1:00 PM ET, poster presentation
June 25, 12:00 – 1:00 PM ET, poster presentation
June 25, 12:00 – 1:00 PM ET, poster presentation
June 25, 12:00 – 1:00 PM ET, poster presentation
The above abstracts and presentations are a sampling of the data that will be presented or published by Novo Nordisk. This press release contains forward-looking statements about investigational products currently in development by Novo Nordisk. As is expected, there is significant risk with drug development and there is no guarantee that future studies will reflect similar results as presented at ADA. For further information about the Novo Nordisk drug pipeline, visit http://www.novonordisk.us. About Novo Nordisk Tresiba®, Fiasp®, NovoLog®, Xultophy® 100/3.6, Ozempic® and Cornerstones4Care® are registered trademarks of Novo Nordisk A/S. Novo Nordisk is a registered trademark of Novo Nordisk A/S. All other trademarks, registered or unregistered, are the property of their respective owners. © 2018 Novo Nordisk All rights reserved. US18CORP00032 June 2018
View original content:http://www.prnewswire.com/news-releases/novo-nordisk-to-present-39-abstracts-at-the-78th-annual-american-diabetes-association-scientific-sessions-300667738.html SOURCE Novo Nordisk |
||
|
||
Copyright 2018 PR Newswire Association LLC. | Back to overview list |